John Dillon

+44 (0)1382 632334
Professor of Hepatology and Gastroenterology


Prof John Dillon is Professor of Hepatology and Gastroenterology, in the School of Medicine, Ninewells Hospital, University of Dundee, as well as being an honorary consultant with NHS Tayside, leading a busy general hepatology service and a research group. He is also clinical lead for Blood Borne Viruses in Tayside. He was a NHS consultant Physician, Gastroenterologist and Hepatologist in Tayside for over 10 years, prior to his move to the University of Dundee.

He chairs the Scottish HCV action plan clinical leads group and is a member of the ministerial advisory group for sexual health and blood borne viruses, as well as chairing the Scottish Liver Diagnostic Care Pathway Steering Group on behalf of Scottish Government. Previously he chaired the testing treatment and care working group of phase 1 of the Scottish Government HCV action Plan and the Hepatitis C SIGN guideline development group.

He graduated in Medicine from St George’s Hospital Medical School, University of London, and subsequently gained his MD based on research performed in the University of Edinburgh while a lecturer in Gastroenterology and Hepatology.


He is a translational researcher, taking clinical problems back and forth across the scientific-clinical interface, looking for solutions. The agenda for this has been defined by the clinical problems faced within clinical practice as a Hepatologist and gastroenterologist. These problems are abnormal liver function tests, Non-alcoholic Fatty liver disease, Hepatitis C and Barrett’s Oesophagus. The common theme within these problems is the pathway of care, identifying those patients who need treatment and bringing that treatment to them, be that looking for new diagnostics, new treatments or new ways of working.

Non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (often associated with obesity or diabetes), affects more than 20% of the Scottish population. The team believe the underlying mechanism of pathogenesis is a failure to adapt to oxidative stress, a classic polygenetic and environmental interaction. They are using proteomic and genomic technologies to generate biomakers for diagnosis and staging of NAFLD, but also to give insights into relevant pathways,

This feeds into the pathway based research in collaboration with Profs John HayesandMike Ashford looking at the master regulator of the initial cellular oxidative stress response Nrf-2, knock out models of this gene being very susceptible to developing the NASH phenotype. The combination of these approaches harnessing the different skills and talents of the researchers is key to bringing about the translation of the discoveries into the therapeutic arena.

To put NAFLD in a population context, the group created ELDIT (Epidemiology of liver disease in Tayside). A grant funded project in collaboration with Prof Peter Donnan using electronic case record and data linkage to diagnose liver disease, estimate its epidemiology and plot its progression on a population basis. This was the first time this has been done for all the diseases of a whole organ system. This led to a project funded by the HTA NHS R&D investigating the natural history of abnormal LFTS in the Tayside population, which has led to the creation of a database of 99,000 patients with 2million LFTs followed for 15 years, this is leading to a decision support tool for the investigation of LFTs for GPs based on the database, which the Biomarkers can be integrated into. This is now being used to create a new diagnostic pathway for liver disease across Scotland.

Hepatitis C

Research in HCV has been built bottom up from the local, to national and now international projects, becoming a recognized centre of excellence. Innovative clinical practice around pathways to diagnosis and treatment, has led to several papers, multiple national and international lecture invitations and our model of care has been adopted across Scotland and in many parts of the UK.

As a result of the reputation gained by this work the team was invited to help establish a UK wide HCV research resource, the aim was to establish a UK bio-repository for HCV research that would become the focus for UK HCV research both for basic science and clinical work. This has now been developed into a consortium of over 40 academic institutions and has been funded by the medical research foundation. The group are also part of the STOPHCV consortium. They also have an active program of clinical trials of HCV therapy with Pharma.

Barrett’s Oesophagus

The current research focusses on investigating the novel bacteria we have detected on Barrett’s mucosa and evaluating its role in disease progression.

Grants and Research Funding

Dr Dillon’s total research grant income jointly obtained with clinical and scientific colleagues locally and in collaboration with other institutions is over £13.4 million, with £9.7 million associated with currently active projects. In addition there have been considerable funds generated by commercial clinical research for both the NHS and University. Funding bodies include the MRC, the Medical Research Foundation, the CSO, HTA and the Department of Trade and Industry, Technology Strategy Board, Tenovus, British Liver Trust, other charities and various industry supported grants.

PhD supervision

PhD studentship 2011-2015. Ahmad Alshehri“Exploring the mechanisms of hepatitis C viral entry into cells and the immune response to viral antigen.”

Dr Helen Steed MD University of Dundee, awarded 2012.

Dr Michael Miller PhD University of Dundee submitted. Biomarkers of Non-alcoholic fatty Liver Disease, awarded 2012.

Dr Katie Blackett PhD University of Dundee awarded 2010. Microbiota of Barrett’s Oesophagus.

Dr Tom Astell-Burt PhD University of St Andrews awarded 2010. Geographies of Hepatitis C’. An investigation into whether long journey-times to healthcare have influenced the likelihood of detection, referral, treatment utilisation and mortality among people infected with the Hepatitis C Virus in Scotland.

Dr George Abouda MD University of Dundee awarded 2009. Studies on the role of H.pylori in Barrett’s Oesophagus.

David McLernon PhD University of Dundee awarded 2008. Studies on the investigation of abnormal liver function tests.

Dr John A Todd MD University of Dundee 2005. Acid suppression in Barrett’s Oesophagus and oesophageal adenocarcinoma.

Dr Christopher Sheen MD University of London 2003. Studies on the epidemiology of simple analgesic use in deliberate self –harm.


Group members

  • Mrs. Shirley A J Cleary
  • Miss Amy Malaguti
  • Mr. Ally Taylor

Lectures and conferences

I have given more than 100 invited lectures at UK and international venues on topics including Hepatitis C, Abnormal liver function tests, NAFLD, Barrett’s and Gastro-oesophageal reflux disease meetings. These include:

  • OESO world organisation for study of oesophageal disease
  • Annual congress of European association for study of the liver (EASL).
  • Multiple Symposia for the Royal College of Physicians,
  • Annual congress of European Association of Clinical Chemists,
  • European Viral Hepatitis Prevention Board
  • Annual meeting British Society of Gastroenterology
  • Annual meeting British association for study of Liver
  • International Pepsin Conference
  • International workshops on Biliary reflux
  • Dundee-Toulouse cancer conference
  • Belfast-Dundee cancer conference
  • Scottish Government HCV action plan conference
  • Mainliners UK annual conference

Multiple lectures to UK and European research groups



My undergraduate teaching experience is extensive having taught in several institutions. In Dundee I facilitate and deliver teaching in lectures, in small groups, in clinical skills in the; wards Endoscopy and out-patients. Additionally I am the convener of the Gastroenterology course within the MB ChB course.



For 12 years I led local GI training, was the Regional speciality advisor and programme director for training for Gastroenterology for the East of Scotland 1998-2010. I was also national training lead from 2008-2010, I served on the Specialty advisory committee for gastroenterology (SAC) to JCHMT/JRCPTB 2004-2010 and the BSG training committee.


I led the creation of endoscopy training courses for upper Gastro-intestinal Endoscopy, colonoscopy and therapeutic endoscopy in Dundee, these were amongst the first in the UK, and have subsequently been officially approved as licensing authorities came into existence. These are intensive “hands on” training courses, sited within the Cuschieri Skills Centre, which is now the nationally recognised Endoscopy Training Centre for Scotland. I was director/lead for endoscopy training from 1997-2011.


Locally I have lead the development and implementation of a multi-disciplinary education program for HCV over the last 10 years, using a variety of educational techniques.

At Scottish and National level, I have been involved leading and delivering numerous educational events for diverse audiences on Hepatitis. For the last 6 years I have co-chaired the Interactive summit on Hepatitis UK(ISH), a national educational and pathway development conference for HCV treatment teams. I have also lead the organisation of a series of annual conferences on Hepatitis B “Scotland and the other Hepatitis virus” for clinicians across the UK.

I have been involved in the production of numerous aids and educational materials for patients affected by hepatitis on behalf of Scottish Government and “star” in a DVD


  • Medical students for intermediate exams and finals at Dundee and Edinburgh.
  • Membership examiner for the Royal College of Physicians.

MDs and PhDs for the universities of Dundee, Edinburgh, Glasgow, Bristol, London and Strathclyde


Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: Implications for reinfection. Heather Valerio, David J Goldberg, James Lewsey, Amanda Weir, Samuel Allen, Esther J Aspinall, Stephen T Barclay, Peter Bramley, John F Dillon, Ray Fox, Andrew Fraser, Peter C Hayes, Hamish Innes, Nicholas Kennedy, Peter R Mills, Adrian J Stanley, Sharon J Hutchinson. Drug and alcohol dependence, 2015;154:125-131.

Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland's experience. Sharon J. Hutchinson, John F. Dillon, Ray Fox, Scott A. McDonald, Hamish A. Innes, Amanda Weir, Allan McLeod, Esther J. Aspinall, Esther J. Aspinall, Norah E. Palmateer, Avril Taylor, Alison Munro, Heather Valerio, Heather Valerio, Gareth Brown, David J. Goldberg et al International Journal of Drug Policy 06/2015; 57.

The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations. A systematic review of the literature. JT Coates, John F Dillon. International Journal of Drug Policy 2015; 06/2015;

Towards a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hamish Innes, Scott A McDonald, John F Dillon, David Goldberg, Stephen T Barclay, Heather Valerio, Ray Fox, Diptendu Bhattacharyya, Andrew Fraser, Peter Bramley, Sharon J Hutchinson. Hepatology. 2015; 62: 355-364.

Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease. Kayleigh L Wood, Michael H Miller and John F Dillon. BMJ Open Gastroenterology 2015

HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: Real world results and modelling of treatment impact. Natasha K. Martin, Graham R. Foster, J. Vilar, Stephen D. Ryder, Matthew E. Cramp, F. Gordon, John F. Dillon, Noel Craine, H. Busse, Amanda J. Clements, Sharon J. Hutchinson, Andrew P. Ustianowski, M. Ramsay, David J. Goldberg, William L. Irving, Vivian D. Hope, Daniela Souza Araújo De Angelis, Marion K. Lyons, Peter T. Vickerman, Matthew Hickman. Journal of Viral Hepatitis 2015;22:399-408

Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public-health outcomes do we value. Hamish Innes, John F Dillon, David Goldberg, and Sharon J Hutchinson. Gut 2014 11/2014

Epidemiology and Population Health"A Systematic Review of the Prevalence of Mildly Abnormal Liver Function Tests and Associated Health Outcomes" Sven Radcke, Aja Louise Murray, John F. Dillon, European Journal of Gastroenterology and Hepatology 2015;27:1-7.

What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C? McDonald, S. A., Innes, H. A., Hayes, P. C., Dillon, J. F., Mills, P. R., Goldberg, D. J., Barclay, S., Allen, S., Fox, R., Fraser, A., Kennedy, N., Bhattacharyya, D. & Hutchinson, S. J. Journal of Hepatology 2015; 62:262-268.

Uptake of hepatitis C specialist services and treatment following diagnosis by dried blood spot in Scotland. McAllister, G., Innes, H., Mcleod, A., Dillon, J. F., Hayes, P. C., Fox, R., Barclay, S. T., Templeton, K., Aitken, C., Gunson, R., Goldberg, D. & Hutchinson, S. J. Journal of Clinical Virology 2014;61:359-364.

Health State Utilities Associated with Attributes of Treatments for Hepatitis C. Matza LS, Sapra S, Kalsekar A, Dillon JF, Davies E, Devine MK, Jordan J, Landrian A, Feeny DH. European Journal of Health Economics 2014;10.

M Anwar, MH Miller, JF Dillon. Systematic review of association of serum bilirubin levels and non-alcoholic fatty liver disease: a feasible therapeutic avenue? World Journal of Pharmacology 2014;3: 209-216.

Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes, but not with insulin resistance. Paul J. Meakin, Sudhir Chowdhry, Ritu S. Sharma, Fiona B. Ashford, Shaun V. Walsh, Rory J. McCrimmon, Albena T. Dinkova-Kostova, John F. Dillon, John D. Hayes, Michael L.J. Ashford. Molecular and Cell Biology 2014

Prediction of liver disease in patients whose liver function tests have been checked in primary care: model development and validation using population-based observational cohorts. David J McLernon, Peter T Donnan, Frank M Sullivan, Paul Roderick, William M Rosenberg, Steve D Ryder, John F Dillon. BMJ open 2014

The Serum Proteome of Non-Alcoholic Fatty Liver Disease - A multimodal approach to discovery of biomarkers of Non-Alcoholic Steatohepatitis. MH Miller, SV Walsh, A Atirh, JTJ Huang, MAJ Ferguson, JFDillon.Journal of Gastroenterology and Hepatology. 2014

Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model. Hamish Innes, David Goldberg, Geoffrey Dusheiko, Peter Hayes, Peter R. Mills, John F. Dillon, Esther Aspinall, Stephen T. Barclay, Sharon J. Hutchinson Journal of Hepatology. 2014;

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease V Bradford, JF Dillon, MH Miller. Hepatic Medicine: Evidence and Research 2014;6:1–10.

McDonald SA, Hutchinson SJ, Innes HA, Allen S, Bramley P, Bhattacharyya D, Carman W, Dillon JF, Fox R, Fraser A, Goldberg DJ, Kennedy N, Mills PR, Morris J, Stanley AJ, Wilks D, Hayes PC. Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically infected with hepatitis C: examining the early impact of Scotland’s Hepatitis C Action Plan. Journal of Viral Hepatitis. 2014;21:.

Innes HA, Hutchinson SJ, Barclay S, Cadzow E, Dillon JF, Fraser A, Goldberg DJ, Mills PR, McDonald SA, Morris J, Stanley A, Hayes P. Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness. Hepatology 2013 Feb; 57 (2): 451-60.

Dry blood spot testing for hepatitis C in people who injected drugs: reaching the populations other tests cannot reach. J M Tait, Brian P Stephens, Paul G McIntyre, Morgan Evans, John F Dillon.

Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett's and oesophageal carcinoma: association or causality? Blackett, K. L., Siddhi, S. S., Cleary, S., Steed, H., Miller, M. H., Macfarlane, S., Macfarlane, G. T. & Dillon, J. F. Alimentary Pharmacology & Therapeutics. 2013; 37: 1084-1092.

HCV treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Natasha K Martin, Peter Vickerman, Jason Grebely, Margaret Hellard, Sharon J Hutchinson, Viviane D Lima, Graham R Foster, John F Dillon, David J Goldberg, Gregory J Dore, Matthew Hickman. Hepatology 2013; 58: 1598-609.

Richard S Tedder and Alison J Rodger, Lori Fries, Samreen Ijaz, Mark Thursz , William Rosenberg, Nikolai Naoumov, Jangu Banatvala, Roger Williams, Geoffrey Dusheiko, Shilpa Chokshi, Terry Wong, Gillian Rosenberg, Sulleman Moreea, Margaret Bassendine, Michael Jacobs, Peter Mills, David Mutimer, Stephen Ryder, Andrew Bathgate, Hyder Hussaini, John Dillon, Mark Wright, George Bird, Jane Collier, Michael Anderson, Anne Johnson for the CUSHI B Study Group. "The Diversity and Management of Chronic Hepatitis B Virus Infections in the UK - A Wake up Call," Clinical Infectious Diseases 2013 56: 951-60.

DJ McLeron, PT Donnan, JF Dillon "Prevalence estimates of diagnosed viral hepatitis B, liver condition outcomes and hospitalisation costs: A population record-linkage study in Tayside, Scotland" Epidemiology and Infection 2013;141: 2122-2130.

David J McLernon, John F Dillon, Frank M Sullivan, Paul Roderick, William M Rosenberg, Stephen D Ryder, PT Donnan. The utility of liver function tests for mortality prediction within one year in primary care using the Algorithm for Liver Function Investigations (ALFI). PLOS ONE 2012 7(12):

Increasing survival of hepatocellular carcinoma patients in Scotland: a review of national cancer registry data. J Kevin Dunbar, John Dillon, O James Garden, David H Brewster. HPB 2013 5:279-85.

Colin N.A. Palmer, Cristina Maglio, Martin Adiels, Carlo Pirazzi, Maria Antonella Burza, Lindsay Burch, Louise Donnelly, Alexander S. Doney, John F Dillon, Mark McCarthy, Andrew T. Hattersley, Tim Frayling, Andrew D. Morris, Jan Boren, Lars Sjöstrom, Peter Jacobson, Lena Carlsson, Stefano Romeo. Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. PLoS ONE 2012 7(6):e39362

Hasnain Jafferbhoy, M H Miller, EB Henry, W Gashau, C Chandra Shekar, M Lockhart, J F DillonSpontaneous bacterial peritonitis prophylaxis in the era of healthcare associated infection. GUT 2012;61:1644-45.

T. Astell-Burt, R. Flowerdew, P.J. Boyle, and J. F. Dillon. Is travel-time to a specialist centre a risk factor for non-referral, non-attendance and loss to follow-up among patients with hepatitis C (HCV) infection? Findings from the 'Epidemiology for Liver Disease in Tayside' study in Scotland. Social Science & Medicine. 2012; 75: 240-247.

Hamish A Innes, Sharon J Hutchinson, Samuel Allen, Diptendu Bhattacharyya, Peter Bramley, Bill Carman, Toby E S Delahooke, John F Dillon, David J Goldberg, Nicholas Kennedy, Peter R Mills, John Morris, Judith Morris, Chris Robertson, Adrian Stanley, Peter Hayes, and the Hepatitis C Clinical Database Monitoring Committee. Ranking predictors of sustained viral response for chronic hepatitis C patients treated with pegylated interferon and ribavirin in Scotland. European J of gastroenterology and hepatology 2012;24: 646-655.

Steed, Helen; Macfarlane, George; Blackett, Katie; Macfarlane, Sandra; Miller, Mike; Bahrami, Bahram; Dillon, John. Bacterial translocation in cirrhosis is not caused by an abnormal small bowel gut microbiota. FEMS Immunology & Medical Microbiology. 2011;63:346-354.

Hamish A Innes, Sharon J Hutchinson, Samuel Allen, Diptendu Bhattacharyya, Peter Bramley, John F Dillon, Ewan Forrest, Andrew Fraser, Ruth Gillespie, David J Goldberg, Nicholas Kennedy, Scott McDonald, Allan McLeod, Peter R Mills, Judith Morris and Peter Hayes, on behalf of the Hepatitis C Clinical Database Monitoring Committee. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology 2011;54: 1547-1558.

Jafferbhoy H, Miller M, McLeod S, Dillon JF. The effectiveness of outreach testing for Hepatitis C in an immigrant Pakistani population. Epidemiology and Infection

H. Jafferbhoy, M.H. Miller, Z. El Wahed, J.F. Dillon. Pre-treatment prediction of response to pegylated-interferon plus ribavarin for chronic hepatitis C using RVR. Journal of Hepatology 2011; 55: 1162–1167.

M. Isabel Lucena, Mariam Molokhia, Yufeng Shen, Thomas J. Urban, Guruprasad P. Aithal, Raúl J. Andrade, Christopher P. Day, Francisco Ruiz-Cabello, Peter T. Donaldson, Camilla Stephens, Munir Pirmohamed, Manuel Romero-Gomez, Jose Maria Navarro, Robert J. Fontana, Michael Miller, Max Groome, Emmanuelle Bondon-Guitton, Anita Conforti, Bruno H. C. Stricker, Alfonso Carvajal, Luisa Ibanez, Qun-Ying Yue, Michel Eichelbaum, Aris Floratos, Itsik Pe'er, Mark J. Daly, David B. Goldstein, John F. Dillon, Matthew R. Nelson, Paul B. Watkins, Ann K. Daly, for the Spanish DILI Registry, EUDRAGENE, DILIN, DILIGEN and International SAEC. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and class II alleles" Gastroenterology. 2011: 141: 338-347.

H. Jafferbhoy M.H. Miller J.K. Dunbar J. Tait S. Mcleod J.F. Dillon. Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection. Journal of Viral Hepatitis 2012;19:112–119.

Miller MH, Ferguson MA, Dillon JF. Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease. Liver International. 2011;31:461-73.

T. Astell-Burt, R. Flowerdew, P.J. Boyle, and J. F. Dillon. "Does geographic access to primary healthcare influence the detection of Hepatitis C?". Social Science & Medicine. 2011;72:1472-81.

M. Cornberg, H. A. Razavi, A. Alberti,E. Bernasconi, C. Cooper, O. Dalgard, J. F. Dillon, M. B. Ferret, R. Flisiak, X. Forns, S. Frankova,A. Goldis, I. Goulis, W. Halota, B. Hunyady, M. Lagging, A. Largen, M. Makara, S. Manolakopoulos, P. Marcellin, R. T. Marinho, S. Pol, T. Poynard, M. Puoti, O. Sagalova, S. Sibbel, K. Simon, C. Wallace, K. Young, C. Yurdaydin, E. Zuckerman, F. Negro &S. Zeuzem, A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver International 2011;31 S2:30-60.

Scott A. McDonald, Sharon J. Hutchinson, Sheila M. Bird, Peter R. Mills, PC Hayes, JF Dillon, David J. Goldberg Excess morbidity in the hepatitis C diagnosed population in Scotland 1991-2006" Epidemiology and Infection 2011;139: 344–353.

Scott A. McDonald, Sharon J. Hutchinson, Peter R. Mills, Sheila M. Bird, Sheila Cameron, John F. Dillon, David J. Goldberg. The influence of hepatitis C and alcohol on liver-related morbidity and mortality in Glasgow's injecting drug user population. Journal of Viral Hepatitis 2011;18:126-133.

H. Jafferbhoy, W. Gashau, JF Dillon. Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection. ClinicoEconomics and Outcomes Research 2010;2:87–96.

Scott A. McDonald, Sharon J. Hutchinson, Sheila M. Bird, Peter R. Mills, Lesley Graham, Chris Stams, JF Dillon, David J. Goldberg The growing contribution of hepatitis C virus infection to liver-related mortality in Scotland" Eurosurveillance 2010;15:pii=19562.

Scott A. McDonald, Sharon J. Hutchinson , Sheila M. Bird, Chris Robertson, Peter R. Mills, John F. Dillon, David J. Goldberg Hospitalisation for an alcohol-related cause among injecting drug users in Scotland: Increased risk following diagnosis with hepatitis C infection. International Journal of Drug Policy 2011;22:63–69.

Tait JM, McIntyre PG, McLeod S, Nathwani D, Dillon JF. The impact of a managed care network on attendance, follow-up and treatment at a hepatitis C specialist centre. Journal of viral hepatitis 2010;17:698-704.

Sudhir Chowdhry; Maiiada H Nazmy; Paul J Meakin; Albena T Dinkova-Kostova; Shaun V Walsh; Tadayuki Tsujita; John F Dillon; Michael L Ashford; John D Hayes. Loss of Nrf2 markedly exacerbates non-alcoholic steatohepatitis. Free Radical Biology & Medicine 2010;48:357-371.

Diagnosis of hepatitis C virus infection in Scotland's injecting drug user population. Scott A. McDonald, Sharon J. Hutchinson, Sheila M. Bird, Peter R. Mills, Chris Robertson, JF Dillon, A. Springbett, David J. Goldberg Epidemiology and Infection (2010), 138, 393–402.

Scott A. McDonald, Sharon J. Hutchinson, Sheila M. Bird, Peter R. Mills, Chris Robertson, John Dillon, Peter Hayes, Toni Williams, David J. Goldberg. Hospitalisation of hepatitis C diagnosed persons in Scotland for decompensated cirrhosis: a population-based record-linkage study. European Journal of Gastroenterology & Hepatology 2010;22:49-57.

McDonald Scott A, Hutchinson Sharon J, Bird Sheila M, Graham Lesley, Robertson Chris, Mills Peter R, Hayes, Peter, Dillon, John F. Goldberg, David J. Association of self-reported alcohol use and hospitalization for an alcohol-related cause in Scotland: a record-linkage study of 23 183 individuals. Addiction 2009:104:593-602.

Ann K Daly, Peter T Donaldson, Pallav Bhatnagar, Yufeng Shen, Itsik Pe'er, Aris Floratos, Mark J Daly, David B Goldstein, Sally John, Matthew R Nelson, Julia Graham, B Kevin Park, John F Dillon, William Bernal, Heather J Cordell, Munir Pirmohamed, Guruprasad P Aithal, Christopher P. Day for the DILIGEN study and International SAE Consortium. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nature Genetics 2009:41;816-U71.